Top Cited Papers
Open Access
Abstract
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.
Funding Information
  • University of Texas MD Anderson Cancer Center (Pancreas Cancer Moonshot)
  • Cancer Prevention and Research Institute of Texas (N/A)
  • Instituto Nacional de Cancerología (NCI CA213233)
  • Instituto Nacional de Cancerología (NCI P01 CA117969)
  • Instituto Nacional de Cancerología (NCI CA195733)
  • University of Texas MD Anderson Cancer Center (Khalifa Bin Zayed Al Nahya Foundation)
  • Instituto Nacional de Cancerología (High Resolution Electron Microscopy Facility Institutional Core Grant CA16672)
  • Instituto Nacional de Cancerología (NIH P30CA16672)
  • Instituto Nacional de Cancerología (MDACC Small Animal Imaging Facility NIH P30-CA016672)
  • Instituto Nacional de Cancerología (5U24-CA126577)

This publication has 34 references indexed in Scilit: